{
    "clinical_study": {
        "@rank": "43551", 
        "arm_group": {
            "arm_group_label": "RO5545965", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This single center, open-label study will evaluate the PK-PDE10A Enzyme Occupancy\n      Relationship of RO5545965 after a single dose in healthy male volunteers by positron\n      emission tomography (PET)."
        }, 
        "brief_title": "A PET Study With RO5545965 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects,  25 to 50 years of age, inclusive; healthy status is defined\n             by absence of evidence of any active or chronic disease\n\n          -  Body mass index (BMI) 18 to 30 kg/m2 inclusive\n\n          -  Male subjects with female partners of child-bearing potential must use two methods of\n             contraception, one of which must be a barrier method (i.e. condom), for the duration\n             of the study and for 30 days after the last dose\n\n        Exclusion Criteria:\n\n          -  History of any clinically significant gastrointestinal, renal, hepatic,\n             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,\n             haematological or allergic disease, metabolic disorder, cancer or cirrhosis\n\n          -  History of clinically significant hypersensitivity or allergic drug reactions\n\n          -  Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse\n\n          -  Regular smoker (> 5 cigarettes, > 1 pipeful or > 1 cigar per day)\n\n          -  Positive for hepatitis B, hepatitis C, or HIV infection\n\n          -  Evidence of significant cardiovascular disease or disorder\n\n          -  Participation in an investigational drug or device study within 3 months prior to\n             first administration of the study drug or within 6 times the elimination half-life,\n             whichever is longer\n\n          -  Previous inclusion in a research and/or medical protocol or any clinical procedures\n             involving nuclear medicine, PET, occupational exposure to ionizing radiation or\n             radiological investigations with significant exposure to radiation, excluding dental\n             X-ray and common X-rays of chest or extremities\n\n          -  Subject has any condition that would prevent an MRI from accurately or safely being\n             performed [eg, claustrophobia, cardiac pacemaker, metallic implants or clips]\n\n          -  Subject unable to lie on his back in the PET or MRI scanner for a period of 90\n             minutes\n\n          -  Contraindication for arterial cannulation\n\n          -  Unsuitable veins for repeated venipuncture"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923025", 
            "org_study_id": "BP28844", 
            "secondary_id": "2013-000538-36"
        }, 
        "intervention": {
            "arm_group_label": "RO5545965", 
            "description": "Single dose", 
            "intervention_name": "RO5545965", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "NW10 7EW"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacodynamics: Brain PDE10 occupancy by RO5545965", 
                "safety_issue": "No", 
                "time_frame": "up to Day 2"
            }, 
            {
                "measure": "PK/PD: Brain PDE10 inhibition in relationship to RO5545965 plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "up to Day 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 12 days"
            }, 
            {
                "measure": "Pharmacokinetics: Plasma concentrations of RO5545965", 
                "safety_issue": "No", 
                "time_frame": "up to Day 5"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}